Fundamental Analysis of IKENA ONCOLOGY INC(NASDAQ:IKNA) stock

Fundamental Rating

Overall IKNA gets a fundamental rating of 4 out of 10. We evaluated IKNA against 195 industry peers in the Pharmaceuticals industry. IKNA has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, IKNA is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

IKNA had negative earnings in the past year.

In the past year IKNA has reported a negative cash flow from operations.

IKNA had negative earnings in each of the past 5 years.

IKNA had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of IKNA (-40.57%) is comparable to the rest of the industry.

IKNA has a Return On Equity (-45.12%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-40.57%
ROE	-45.12%
ROIC	N/A

ROA(3y)-29.72%

ROA(5y)-27%

ROE(3y)-34.45%

ROE(5y)-48.44%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IKNA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IKNA does not have a ROIC to compare to the WACC, probably because it is not profitable.

IKNA has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, IKNA has more shares outstanding

There is no outstanding debt for IKNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

IKNA has an Altman-Z score of -0.05. This is a bad value and indicates that IKNA is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -0.05, IKNA perfoms like the industry average, outperforming 51.30% of the companies in the same industry.

IKNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.05

ROIC/WACCN/A

WACC9%

2.3 Liquidity

A Current Ratio of 15.85 indicates that IKNA has no problem at all paying its short term obligations.

The Current ratio of IKNA (15.85) is better than 88.08% of its industry peers.

A Quick Ratio of 15.85 indicates that IKNA has no problem at all paying its short term obligations.

IKNA has a better Quick ratio (15.85) than 88.08% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	15.85
Quick Ratio	15.85

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IKNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.87%, which is quite good.

Looking at the last year, IKNA shows a very negative growth in Revenue. The Revenue has decreased by -78.06% in the last year.

Measured over the past years, IKNA shows a very strong growth in Revenue. The Revenue has been growing by 56.05% on average per year.

EPS 1Y (TTM)10.87%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%15.38%

Revenue 1Y (TTM)-78.06%

Revenue growth 3Y-0.11%

Revenue growth 5Y56.05%

Sales Q2Q%-100%

3.2 Future

IKNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.65% yearly.

Based on estimates for the next years, IKNA will show a very strong growth in Revenue. The Revenue will grow by 26.14% on average per year.

EPS Next Y24.1%

EPS Next 2Y16.98%

EPS Next 3Y13.96%

EPS Next 5Y8.65%

Revenue Next Year-73.39%

Revenue Next 2Y-48.42%

Revenue Next 3Y-35.68%

Revenue Next 5Y26.14%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IKNA. In the last year negative earnings were reported.

Also next year IKNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as IKNA's earnings are expected to grow with 13.96% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.98%

EPS Next 3Y13.96%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IKNA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IKENA ONCOLOGY INC

NASDAQ:IKNA (7/1/2024, 7:00:02 PM)

After market: 1.65 0 (0%)

1.65

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap79.63M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-40.57%
ROE	-45.12%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	15.85
Quick Ratio	15.85
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)10.87%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y24.1%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-78.06%

Revenue growth 3Y-0.11%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

IKENA ONCOLOGY INC (IKNA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens